STX209 · program
Arbaclofen for Fragile X syndrome
- FDA Orphan Drug Designation (Fragile X Syndrome), Per Allos Pharma'S 2023-09-18 Release; Grant Date Not Disclosed
Indications for STX209: Autism spectrum disorder · Phase 2 Multiple sclerosis · Phase 3 Fragile X syndrome · Phase 3
Arbaclofen (STX209), a selective GABA-B receptor agonist, for social avoidance and behavioural symptoms of fragile X syndrome (FXS). The rationale comes from Fmr1 knockout models, where arbaclofen reversed disease-related pathology. Seaside Therapeutics' Phase 2 crossover trial (NCT00788073; 63 subjects aged 6-39) missed its primary irritability endpoint, though a post hoc analysis showed benefit on ABC Social Avoidance. Two Phase 3 trials followed. The adolescent/adult trial 209FX301 (NCT01282268; 125 subjects) showed no benefit on any measure. The child trial 209FX302 (NCT01325220; 172 children aged 5-11) missed the Social Avoidance primary endpoint, but the highest dose (10 mg TID) separated from placebo on ABC Irritability and the Parenting Stress Index. Seaside terminated the open-label extension in May 2013, citing resource limitations. Allos Pharma, founded by Seaside's founders, licensed arbaclofen for FXS in November 2020. In 2023 it said it had reached alignment with the FDA and the fragile X community on a confirmatory Phase 3 design, and it lists an FDA orphan designation in FXS. No new FXS trial is registered on ClinicalTrials.gov as of 2026-10-28. Mirum Pharmaceuticals' FY2025 10-K still lists Allos's arbaclofen among FXS programs in clinical development.
Development timeline
- FDA regulatory meeting / outcomeAllos reports FDA alignment on a confirmatory Phase 3 design for arbaclofen in fragile X↗
- Allos Pharma announces exclusive license rights to arbaclofen in fragile X syndrome and says it plans to take it through NDA approval.↗
- missedPhase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale.↗
- missedPhase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity.↗
- missedPhase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization.↗
- Phase 3 child study 209FX302 (NCT01325220; fixed doses, ages 5-11) starts; the adolescent/adult Phase 3 209FX301 (NCT01282268) runs in parallel.
- Seaside Therapeutics starts Phase 2 study 22001 (NCT00788073): a placebo-controlled crossover trial of STX209 in 63 subjects with fragile X syndrome.
Readouts
- 2017-06-12ReportedFull resultsmissedNCT01282268
Phase 3 209FX301 (adolescents/adults aged 12-50, flexible dose, 125 randomised): no benefit of arbaclofen over placebo on any measure, including the primary ABC-CFX Social Avoidance subscale. ↗
- 2017-06-12ReportedFull resultsmissedNCT01325220
Phase 3 209FX302 (children aged 5-11, 172 randomised, fixed doses): missed the primary ABC-CFX Social Avoidance endpoint. The 10 mg TID group beat placebo on ABC-CFX Irritability (p=0.03) and the Parenting Stress Index (p=0.03), with trends on Social Avoidance and Hyperactivity. ↗
- 2012-09-19ReportedFull resultsmissedNCT00788073
Phase 2 crossover of STX209 in 63 FXS subjects: no difference from placebo on the primary ABC-Irritability endpoint; post hoc benefit on ABC Social Avoidance and, in the more socially impaired subgroup, on Vineland-II Socialization. ↗
Clinical trials in Fragile X syndrome
NCT01555333209FX303Phase 3Discontinuedn=357
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome
NCT01325220209FX302Phase 3Completedn=172
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Children With Fragile X Syndrome
NCT01282268209FX301Phase 3Completedn=125
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Function in Adolescents and Adults With Fragile X Syndrome
NCT0078807322001Phase 2Completedn=63
A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Arbaclofen oral (orally disintegrating) tablets, 5-20 mg BID-TID AIMS-2-TRIALS-CT1 (NCT03682978): orally disintegrating tablets of 5, 10, 15 and 20 mg, flexibly titrated over 5 weeks and stratified by age. Ages 5-11 went from 5 mg BID up to 15 mg TID; ages 12-17 went from 5 mg QD up to 20 mg TID. Treatment lasted 16 weeks. The Canadian ARBA trial (NCT03887676) used the same orally disintegrating tablet strengths. | Oral | Three times daily | — |
Mechanism of action
Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.
| Target | Action | Affinity |
|---|---|---|
| GABA-B receptorprimaryGABBR1 | Agonist | —ⓘ |
← Full STX209 compound page (identity, identifiers, all indications)
Sources
- Allos Pharma Inc. Expands Intellectual Property Rights for Arbaclofen (2023-09-18, PR Newswire wire copy) — Allos Pharma Inc. (via BioSpace)
- Allos Pharma secures exclusive license on arbaclofen in Fragile X Syndrome (2020-11-19, wire copy) — Allos Pharma Inc. (via BioSpace)
- Berry-Kravis E, et al. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord 2017;9:3 — Journal of Neurodevelopmental Disorders / PubMed
- Berry-Kravis EM, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012;4(152):152ra127 — Science Translational Medicine / PubMed
- NCT00788073 (22001) — Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01282268 (209FX301) — Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01325220 (209FX302) — Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT01555333 (209FX303) — An Open Label Extension Study in Subjects With Fragile X Syndrome — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03682978 (AIMS2-CT-01) — Arbaclofen in Children and Adolescents With ASD — ClinicalTrials.gov (U.S. National Library of Medicine)
- Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed